Recent Updates
Recently added Catalysts

Daptomycin

Phase 3

Skin Diseases | Small molecule | Dermatology |AstraZeneca PLC|Last Updated: Mar 9, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment265
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00772447China Registration Study in Patients With Skin InfectionsPHASE3 COMPLETED 265Sep 1, 2008Sep 1, 2010Mar 9, 201513 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)
baseline to TOC(test of cure), for up to 4 weeks

Erythrocyte volume fraction means under certain conditions, after centrifugation pressing, the percentage of erythrocyte volume in the total volume of blood

Change in Creatinine Clearance
baseline to TOC(test of cure), for up to 4 weeks
Change in Serum Total Creatine Phosphokinase (CPK)
baseline to TOC(test of cure), for up to 4 weeks
Change in Urine pH
baseline to TOC(test of cure), for up to 4 weeks
Shift in ECG
baseline to TOC(test of cure), for up to 4 weeks

percentage of patients who were primarily tested as normal ECG at baseline and changed into abnormal ECG at TOC visit in all the patients with normal ECG at baseline

Secondary Endpoints
Blinded Investigator's Assessement of Clinical Response at TOC(Test of Cure)
baseline and TOC, for up to 4 weeks
Blinded Investigator's Assessement of Clinical Response at EOT(End of Therapy)
baseline and EOT(end of therapy), for up to 2 weeks
Microbiological Response at TOC(Test of Cure)
baseline and TOC, for up to 4 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AZ drugEXPERIMENTALDaptomycin
ComparatorACTIVE_COMPARATORVancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
Interventions
NameTypeDescription
DaptomycinDRUG4mg/kg IV ; Q 24 hr (once every 24 hours)
VancomycinDRUGVancomycin - 1g per 12 hrs, for 7-14 days Or switch to Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin: \- 1 g every 6 hours or 2 g every 8 hours
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria: * Provision of inform consent * A diagnosis of of complicated skin and skin structure infection known or suspected to be due to Gram-positive bacteria * Diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor, including infections inv...

Countries:China
Unlock Eligibility Criteria